Several characteristics have been predictive of outcome of therapy for relapsed or "primary refractory" acute myelogenous leukemia (AML).'-4 Among these are duration of first complete remission (CR) and the number of, and response to, prior salvage regimens. Using these covariates, we have developed a system that stratifies patients by probability of response to previous salvage agents. This system may be useful when comparing new salvage regimens and when considering which patients might be candidates for phase I studies.
were 11 of 14, 14 of 22, 21 of 104, and 0 of 44, respectively, in the four groups. Applied prospectively to the 64 salvage AML, non-APL patients treated without transplantation since 1995, the scheme's four groups had CR rates of 3 of 3, 4 of 14, 4 of 33, and 0 of 19, respectively. Tested in patients treated from 1986 through 1989, CR rates were 8 of 11, 13 of 30, 23 of 135, and 0 of 74 in groups 1 through 4, respectively.
Systems including more covariates, eg, cytogenetics, have been examined. Not only is complexity increased, but also general applicability may be decreased. Equally importantly, as more covariates are included, the ability of a prognostic system to stratify future patients often decreases ("overfitting").' Such was the case when more complex models based on our 1991 through 1994 data were applied to 1995 and 1996. We use the four-group system described above both to guide therapy and to compare new salvage regimens. Patients in group 1 (mean CR rate with prior therapies, about 70%) receive similar anthracycline + ara-C-based regimens as newly diagnosed patients, whom they resemble prognostically. In contrast, patients in group 4 (mean CR rate, < 1 %) receive phase I agents.
Phase I1 studies are conducted separately (but simultaneously) in patients in groups 2 (mean CR rate, 40%) and 3 (mean CR rate, 10% to 20%). Among the advantages of this method are (1) reduction in the heterogeneity that results if patients in groups 2 and 3 (or patients in groups 2, 3, and 4) are taken as one group, as is common practice? with heterogeneity increasing the chances of falsely negative or falsely positive results when testing new agents; and (2) formal definition of a group (group 2) that may be sufficiently favorable prognostically to avoid the false-negative that presumably results if new regimens are only examined in the least "favorable" patient^.'.^.' Although randomized phase 11 designs have been proposed to reduce heterogeneity among groups of patients treated with different agents,' the sample sizes envisioned in these designs are insufficient for this purpose in the absence of stratification, using a system such as that proposed above. Although the need to test new agents separately in different strata potentially increases phase II sample size, Bayesian pre-phase I1 selection designs effectively address the issue of sample size.' We believe these designs together with the stratification system outlined here represent improvements in methodology for testing new agents in AML. 
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